TOKYO, Dec. 11, 2018 /PRNewswire/ —  Mundipharma and Hisamitsu Pharmaceutical have agreed that Hisamitsu Pharmaceutical will end distribution of dermally absorbed buprenorphine adhesive agent Norspan^® Tape (buprenorphine) in Japan on 28 February 2019, and transfer exclusive distribution to Mundipharma.

Mundipharma acquired the marketing approval of Norspan^® in February 2011 and Hisamitsu Pharmaceutical began distribution that same year. Mundipharma’s distribution infrastructure in Japan is now fully developed, which led to this agreement.

Norspan^® is indicated for the relief of chronic pain associated with osteoarthritis and lower back pain. Its safety and efficacy has been studied in 10 clinical trials.[i]

Mundipharma CEO, Raman Singh, said: “Mundipharma Japan has grown tremendously since 2011, and now has a fully-scaled distribution network, so this was a logical agreement to make.

“Mundipharma has expertise distributing Norspan^® in other countries in the region, which are transferable and will also help ensure that this important medicine continues to be accessible to patients in need in Japan.”

About Mundipharma

Mundipharma is a network of independent associated companies which are privately owned entities. Mundipharma is a prime example of an organization that consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.mundipharma.com.sg

Logo – http://photos.prnasia.com/prnh/20150302/8521501264LOGO